Northwest Biotherapeutics (NWBO) Net Equity Issued and Repurchased (2014 - 2026)

Northwest Biotherapeutics' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 43.39% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $17.1 million (up 76.25% YoY), while the FY2025 annual figure was $19.3 million, up 135.57% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $2.9 million, up from $2.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $7.8 million in Q4 2022, with the low at -$1.8 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $3.5 million (2023), against an average of $3.7 million.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 152.75% in 2024, then jumped 1100.96% in 2025.
• Northwest Biotherapeutics' Net Equity Issued and Repurchased stood at $7.8 million in 2022, then slumped by 55.81% to $3.4 million in 2023, then sank by 152.75% to -$1.8 million in 2024, then jumped by 211.33% to $2.0 million in 2025, then soared by 43.92% to $2.9 million in 2026.
• Business Quant data shows NWBO's Net Equity Issued and Repurchased at $2.9 million in Q1 2026, $2.0 million in Q4 2025, and $4.9 million in Q3 2025.